Onkologie. 2019:13(1):37-42 | DOI: 10.36290/xon.2019.007

Testicular tumours

Nikol Rušarová, Hana Študentová, Marie Bartoušková
Onkologická klinika Fakultní nemocnice Olomouc

Germ cell tumours are the most common malignancies diagnosed in young men. In the recent years, as is also the case with a
number of other malignancies, their incidence appears to have an increasing trend; however, particularly due to interdisciplinary
collaboration of urologists and clinical oncologists, the treatment of these patients is very successful. It is a group of tumours with
a very good prognosis and, even in the case of advanced disease, many patients can be cured completely.

Keywords: germ cell tumours, seminoma, non-seminoma, chemotherapy, inguinal

Published: March 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rušarová N, Študentová H, Bartoušková M. Testicular tumours. Onkologie. 2019;13(1):37-42. doi: 10.36290/xon.2019.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [on-line]. Masarykova univerzita, [2005], [cit. 2018-10-28]. Dostupný z URL: < http://www.svod.cz >.
    2. Stevenson SM, Lowrance WT. Epidemiology and Diagnosis of Testis Cancer. Urol Clin North Am 2015; 42: 269-275. Go to original source... Go to PubMed...
    3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30. Go to original source...
    4. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol 2005; 174: 1819-1822. Go to original source... Go to PubMed...
    5. Oh J, Landman J, Evers A, et al. Management of the postpubertal patient with cryptorchidism: an updated analysis. J Urol 2002; 167: 1329-1333. Go to original source... Go to PubMed...
    6. Ulbright TM. The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them. Adv Anat Pathol 2008; 15: 18-27. Go to original source... Go to PubMed...
    7. Howitt BE, Berney DM. Tumors of the Testis: Morphologic Features and Molecular Alterations. Surg Pathol Clin 2015; 8: 687-716. Go to original source... Go to PubMed...
    8. Mostofi FK, Sesterhenn IA, Davis CJ Jr. Developments in histopathology of testicular germ cell tumors. Semin Urol 1988; 6: 171-182. Go to PubMed...
    9. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-254. Go to original source... Go to PubMed...
    10. Tseng A Jr, Horning SJ, Freiha FS, et al. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer 1985; 56: 2534-2538. Go to original source... Go to PubMed...
    11. Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol 2010; 21: 104-108. Go to original source... Go to PubMed...
    12. McKenney JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 2007; 14: 69-92. Go to original source... Go to PubMed...
    13. Benson CB. The role of ultrasound in diagnosis and staging of testicular cancer. Semin Urol 1988; 6: 189-202. Go to PubMed...
    14. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603. Go to original source... Go to PubMed...
    15. Hori K, Uematsu K, Yasoshima H, et al. Testicular seminoma with human chorionic gonadotropin production. Pathol Int 1997; 47: 592-599. Go to original source... Go to PubMed...
    16. Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clin Biochem 2004; 37: 549-561. Go to original source...
    17. Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28: 3388-3404. Go to original source... Go to PubMed...
    18. Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12: 120-126. Go to original source... Go to PubMed...
    19. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399. Go to original source...
    20. Novotný J, Vítek P, a Kleibl Z. Onkologie v klinické praxi: standardní přístupy v diagnostice a léčbě vybraných zhoubných nádorů. 2. vydání. Praha: Mladá fronta, 2016.
    21. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-1039. Go to original source... Go to PubMed...
    22. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev 2011; CD 007853. Go to original source... Go to PubMed...
    23. Mir MC, Pavan N, Gonzalgo ML. Current Clinical Applications of Testicular Cancer Biomarkers. Urol Clin North Am 2016; 43: 119-125. Go to original source... Go to PubMed...
    24. Petersen PM, Skakkebaek NE, Vistisen K, et al. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999; 17: 941-947. Go to original source... Go to PubMed...
    25. Stenning S, Oliver T, Mead B, Gabe R. Carboplatin in clinical stage I seminoma: a valuable option for patient management. J Clin Oncol 2011; 29: 4210-4219. Go to original source... Go to PubMed...
    26. Yu HY, Madison RA, Setodji CM, et al. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009; 27: 4327-4332. Go to original source... Go to PubMed...
    27. Vesprini D, Chung P, Tolan S, et al. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer 2012; 118: 5245-5250. Go to original source... Go to PubMed...
    28. De Wit R, Roberts J, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 2001; 19: 1629-1640. Go to original source... Go to PubMed...
    29. Fossa SD, Kaye SB, Mead GM, et al. filgrastim during combination chemotherapy of patients with poor prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer Genitourinary Group and the Medical Research Council Testicular Cancer Working Party. J Clin Oncol, 1998; 16: 716-724. Go to original source... Go to PubMed...
    30. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002; 168(5):1975-1979. Go to original source... Go to PubMed...
    31. Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000; 163: 1721-1724. Go to original source... Go to PubMed...
    32. Alberts P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposin plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-2972. Go to original source... Go to PubMed...
    33. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128. Go to original source... Go to PubMed...
    34. Kondagunta GV, Motzer RJ. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors. Urol Clin North Am 2007; 34: 179-185. Go to original source... Go to PubMed...
    35. Ravi P, Gray KP, O'Donnell EK, et al. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol 2014; 25(2): 331-338. Go to original source... Go to PubMed...
    36. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317(23): 1433-1438. Go to original source... Go to PubMed...
    37. Tjulandin SA, Garin AM, Mescheryakov AA, et al. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 1993; 4: 663-667. Go to original source... Go to PubMed...
    38. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11: 598-606. Go to original source... Go to PubMed...
    39. Bokemeyer C, Köhrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7: 1015-1021. Go to original source... Go to PubMed...
    40. Horwich A, Sleijfer DT, Foss? SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15: 1844-1852. Go to original source... Go to PubMed...
    41. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refraktory germ cell cancer:A study of the German Testicular Cancer Study Group, J Clin Oncol. 2004; 22: 108-114. Go to original source... Go to PubMed...
    42. Feldman DR, Huddart R, Hall E, et al. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer 2011; 2: 374-377. Go to original source... Go to PubMed...
    43. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11: 1-20. Go to original source...
    44. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56: 2765-2770. Go to original source...
    45. Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116: 2322-2331. Go to original source... Go to PubMed...
    46. Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol 2016; 34: 2712-2720. Go to original source... Go to PubMed...
    47. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.